Wells Fargo Initiates Nuvalent with Overweight Rating and $116 Price Target

Key Facts

1Wells Fargo initiated coverage on Nuvalent (NUVL) with an 'Overweight' rating and a price target of $116.

2The firm anticipates two potential FDA approvals for zidesamtinib and neladalkib within the next 12 to 18 months.

3Zidesamtinib is expected to become a standard of care for ROS1-positive non-small cell lung cancer treatment.

Wells Fargo has initiated coverage on biotech firm Nuvalent Inc. (NUVL) with an 'Overweight' rating and a price target of $116 per share. The bullish outlook is primarily driven by the strong clinical potential of the company's oncology pipeline, specifically its lead candidates zidesamtinib and neladalkib. Analysts anticipate that both drugs could receive FDA approvals within the next 12 to 18 months, marking a significant milestone for the firm. Zidesamtinib, in particular, is expected to become a standard of care for patients with ROS1-positive non-small cell lung cancer. The initiation also highlights Nuvalent's solid financial position, which provides a stable foundation for its upcoming commercialization efforts. This positive assessment underscores growing investor confidence in the company's ability to deliver breakthrough treatments in the oncology space.